Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib

Naoki Fukuda, Kazuhisa Toda, Yu Fujiwara, Xiaofei Wang, Akihiro Ohmoto, Tetsuya Urasaki, Naomi Hayashi, Yasuyoshi Sato, Kenji Nakano, Mayu Yunokawa, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Background/Aim: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer (ATC). However, tumor markers for ATC treated with lenvatinib is lacking. The aim of this study was to explore whether the neutrophil-to-lymphocyte ratio (NLR) can be a tumor marker for ATC treated with lenvatinib. Patients and Methods: We retrospectively analyzed the prognostic significance of the NLR in 13 ATC patients treated with lenvatinib. Results: The disease control rate was better in patients with lower NLR (<8; 89%) than higher NLR (≥8; 25%) (p=0.05). Median progression-free survival and overall survival were longer in patients with lower NLR than higher NLR (4.0 vs. 1.6 months, p<0.05; and 10.2 vs. 3.8 months, p<0.05, respectively). Patients whose NLR on day 14 decreased compared to baseline had a slightly higher overall response rate than patients without NLR decrease (42.9% vs. 0%, p=0.19). Conclusion: The baseline NLR is a potential prognostic marker, and the change of NLR can be an early indicator of response for ATC patients treated with lenvatinib.

Original languageEnglish
Pages (from-to)2859-2864
Number of pages6
JournalIn Vivo
Issue number5
StatePublished - Sep 2020
Externally publishedYes


  • Anaplastic thyroid cancer
  • Lenvatinib
  • Neutrophil-to-lymphocyte ratio
  • Prognostic factors


Dive into the research topics of 'Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib'. Together they form a unique fingerprint.

Cite this